CLAIMS as filed in the Amendment under PCT Article 34

1. (Amended) A pharmaceutical preparation with binding affinity for plasma protein which comprises a single or plural second drug, characterized in that the second drug has binding affinity for the same plasma protein for which a first drug has binding affinity and the pharmaceutical preparation is administered simultaneously with the first drug or before or after the administration of the first drug to thereby regulate the binding of the first drug to the plasma protein.

2. (Amended) The pharmaceutical preparation according to Claim 1, wherein the second drug has binding affinity to the same binding sites on the plasma protein to which the first drug has binding affinity.

3. (Amended) The pharmaceutical preparation according to Claim 1 or 2, wherein the first drug is a radiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use.

4. (Amended) The pharmaceutical preparation according to Claim 3, wherein the radiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use is radiolabeled with one nuclide selected from the group consisting of 11-carbon ($^{11}C$), 15-oxygen ($^{15}O$), 18-fluorine, ($^{18}F$), 32-phosphorus ($^{32}P$), 59-iron ($^{59}Fe$), 67-copper ($^{67}Cu$), 67-gallium ($^{67}Ga$), 81m-krypton ($^{81m}Kr$), 81-rubidium ($^{81}Rb$), 89-strontium ($^{89}Sr$), 90-yttrium ($^{90}Y$),

99m-technetium ($^{99m}$Tc), 111-indium ($^{111}$In), 123-iodine ($^{123}$I), 125-iodine ($^{125}$I), 131-iodine ($^{131}$I), 133-xenon ($^{133}$Xe), 117m-tin ($^{117m}$Sn), 153-samarium ($^{153}$Sm), 186-rhenium ($^{186}$Re), 188-rhenium ($^{188}$Re), 201-thallium ($^{201}$Tl), 212-bismuth ($^{212}$Bi), 213-bismuth ($^{213}$Bi) and 211-astatine ($^{211}$At).

5. (Amended) The pharmaceutical preparation according to Claim 3, wherein the first drug has one group labeled with nuclide and the group is selected from the group consisting of bisaminothiol or its derivatives, monoaminomonoamidobisthiol or its derivatives, bisamidobisthiol or its derivatives, mercaptoacetyl-glycylglycylglycine or its derivatives, hexamethylpropyleneamineoxime or its derivatives, ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin) or its derivatives, 2,3-dimercaptosuccinic acid or its derivatives, ethylenecysteine dimer derivatives, methoxyisobutylisonitrile derivatives, polyamine derivatives, pyridoxylydeneaminate derivatives, methylene diphosphonate, hydroxymethylene diphosphonate derivative, $\beta$-methyl-$\omega$-phenylpentadecanoic acid or its derivatives, N-isopropylamphetamine, hippuric acid and benzylguanidine and tropane derivatives.

6. (Amended) The pharmaceutical preparation according to any one of claims 1 to 3, wherein the single or plural second drug is selected from the group consisting of bucolome, cefazolin, etoposide, phenylbutazone, aspirine, salicylic acid, cefatriaxone,

sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil and disopyramide.

7. A pharmaceutical preparation characterized by regulating binding affinity of a first drug for plasma protein, which comprises a first drug with binding affinity for plasma protein and a single or plural second drug with binding affinity for the same plasma protein, for which the first drug has binding affinity.

8. The pharmaceutical preparation according to Claim 7, wherein each of the first drug and the second drug is separately filled in a container, and prepared as kit form for supply.

9. The pharmaceutical preparation according to Claim 7 or 8, wherein the second drug has binding affinity to the same binding sites on the plasma protein, to which the first drug has binding affinity.

10. The pharmaceutical preparation according to any one of Claims 7 to 9, wherein the first drug is a radiodiagnostic drug for in vivo use or a radiotherapeutic drug for in vivo use.

11. The pharmaceutical preparation according to Claim 10, wherein the radiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use is radiolabeled with one nuclide selected from the group consisting of 11-carbon ($^{11}C$), 15-oxygen ($^{15}O$), 18-fluorine ($^{18}F$), 32-phosphorus ($^{32}P$), 59-iron ($^{59}Fe$), 67-copper ($^{67}Cu$), 67-gallium ($^{67}Ga$), 81m-krypton ($^{81m}Kr$), 81-

rubidium ($^{81}$Rb), 89-strontium ($^{89}$Sr), 90-yttrium ($^{90}$Y), 99m-technetium ($^{99m}$Tc), 111-indium ($^{111}$In), 123-iodine ($^{123}$I), 125-iodine ($^{125}$I), 131-iodine ($^{131}$I), 133-xenon ($^{133}$Xe), 117m-tin ($^{117m}$Sn), 153-samarium ($^{153}$Sm), 186-rhenium ($^{186}$Re), 188-rhenium ($^{188}$Re), 201-thallium ($^{201}$Tl), 212-bismuth ($^{212}$Bi), 213-bismuth ($^{213}$Bi) and 211-astatine ($^{211}$At).

12. The pharmaceutical preparation according to Claim 10, wherein the first drug has one group labeled with nuclide and the group is selected from the group consisting of bisaminothiol or its derivatives, monoaminomonoamidobisthiol or its derivatives, bisamidobisthiol or its derivatives, mercapto-acetylglycylglycylglycine or its derivatives, hexamethylpropyleneamineoxime or its derivatives, ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin) or its derivatives, 2,3-dimercaptosuccinic acid or its derivatives, ethylenecysteine dimer derivatives methoxyisobutylisonitrile derivatives, polyamine derivatives, pyridoxylydeneaminate derivatives, methylene diphosphonate, hydroxymethylene diphosphonate derivatives, $\beta$-methyl-$\omega$-phenylpentadecanoic acid or its derivatives, N-isopropylamphetamine, hippuric acid, benzylguanidine and tropane derivatives.

13. The pharmaceutical preparation according to any one of Claims 7 to 10, wherein the single or plural second drugs is selected from the group consisting of bucolome, cefazolin, etoposide, phenylbutazone,

aspirine, salicylic acid, ceftriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-2-naphthylacetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil and disopyramide.

add 91